Q1 FY27 results show sharp revenue decline and PAT turned negative

Revenue DeclinePat NegativeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹14.53

prior close

₹13.81

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-5.1% vs market

Pharmaceuticals peers, median of 166sector+0.1%-5.1% vs sector

On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0+0.2-5.1+0.1-5.1

Next day

-9.7+0.2-9.9-0.2-9.5

-14.2+0.4-14.5-0.2-14.0

-18.4+0.7-19.2-0.1-18.3

-22.5+0.1-22.6-1.4-21.1

-18.4+0.7-19.0-0.8-17.6

-19.5+1.2-20.7-0.5-19.0

15d

+0.3+0.7-0.4+0.3+0.0

+40.0-1.2+41.2-0.2+40.2

+65.2-1.1+66.3-2.4+67.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma's Q1 FY27 (ended June 30, 2026) results show total income fell to ₹8.91 lakh from ₹100.30 lakh in Q1 FY26, a drop of about 91%. Other income was the only revenue source. PAT turned negative at ₹(1.61) lakh versus a profit of ₹66.90 lakh last year. EPS stood at ₹0.22 vs ₹0.48. A one-time OCI gain of ₹31.73 lakh on fair valuation of financial assets boosted overall profit for the period to ₹30.12 lakh.

Likely market impact

Sharp revenue shrinkage and a loss at the PAT level signal weak operations; OCI gain masks the underlying weakness.